Momenta Phama (MNTA) Misses Q1 EPS by 15c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. META
6. BA
7. SPY
8. INTC
9. JBLU
10. HOOD

Go back to Momenta Phama (MNTA) Misses Q1 EPS by 15c

Momenta Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update

May 8, 2018 7:01 AM EDT

CAMBRIDGE, Mass., May 08, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today reported its financial results for the first quarter ended March 31, 2018 and provided a corporate update.

We made important progress in the first quarter of 2018 across our complex generic, biosimilar and novel drug portfolios. Importantly, Glatopa 40 mg/mL received FDA approval and, with Sandozs commercial launch now underway, we look forward to the potential for accelerated adoption by customers as the year progresses. In addition, we are looking forward to the start-up of the pivotal patient trial for... More